SINOVAC BIOTECH LTD financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q4 2024.

Symbol
SVA on Nasdaq
Location
Beijing
Fiscal year end
31 December
Latest financial report
30 Apr 2026

Shareable Research Card

SVA - SINOVAC BIOTECH LTD Financial Facts

SVA - SINOVAC BIOTECH LTD has a source-backed company facts page for reviewing reported financial metrics, periods, and linked metric histories.

Start with the latest metric summary, then open metric histories or cross-company rankings to compare the same SEC-backed facts.

Context
Latest metrics period: Q4 2024
Latest reported value
Current Ratio 7.33x

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.

Open stable link Open latest 10-Q/10-K hub

Return Loop

Why revisit this company facts page

Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.

Latest source-backed update
Latest metrics period Q4 2024
Why come back
Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
  • Current latest metrics period: Q4 2024.
  • Most recent SEC facts end date on this page: 31 Dec 2024.
  • Save this filer to return when the next filing-backed metric period changes the picture.

Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.

Create account to save this filer Open latest 10-Q/10-K hub

Latest update

Latest update for SVA - SINOVAC BIOTECH LTD

New fact period available

Latest financial period: Q4 2024. Reopen this facts page to verify the newest reported period against the prior baseline.

Update date

30 Apr 2026

Page type

Company facts

Latest period

Q4 2024

SEC-backed company facts were refreshed from filings filed on 30 Apr 2026.

Open recent updates hub Open latest 10-Q/10-K hub

Benchmark Context

How Current Ratio compares

Current Ratio is down about 18% versus the comparable prior period.

Compared with

Compared with SINOVAC BIOTECH LTD's recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.

Why this is notable

Current Ratio already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.

  • Latest comparable period on this page: Q4 2024.
  • Peer context will appear when enough companies report a comparable value for this metric.
  • Open the metric history first if you want to verify the exact period-to-period change.

Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.

Open latest 10-Q/10-K hub

Save this filer page

Create a free account to keep this page in your watchlists and return after a new SEC filing changes the record here.

Create free account to save and revisit this page

Quick Takeaways

  • SVA - SINOVAC BIOTECH LTD financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q4 2024.
  • Headline metric: Current Ratio 7.33x.

What Changed

  • Current Ratio YoY change: -18%.
  • Most recent SEC facts end date: 31 Dec 2024.

Why This Matters

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Source Evidence

Based on latest 10-Q/10-K

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.

See Original Filing

Latest SEC snapshot (2024-12-31) highlights Current Ratio 7.33x and Quick Ratio 7.26x.

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

24.6/100

Weak Confidence low

Financial Health

Current Ratio
7.33x
Quick Ratio
7.26x

Strengths

No strong signals yet.

Watchpoints

Current Ratio and Quick Ratio

Key metrics snapshot

Financial Health

Metric Latest value YoY change
Current Ratio 7.33x -18%
Quick Ratio 7.26x -18%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 71,860,702 -28%
Common Stock, Shares, Outstanding 71,860,702 0%
Common Stock, Value, Issued $72,000 0%

Supporting Metrics

These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.

Metric Latest value YoY change
Accounts Receivable, after Allowance for Credit Loss, Current $306,567,000 -28%
Accrued Liabilities, Current $156,595,000 -16%
Accumulated Other Comprehensive Income (Loss), Net of Tax $707,806,000 -26%
Assets $12,337,281,000 -9.4%
Assets, Current $10,644,515,000 -8.2%
Cash and Cash Equivalents, at Carrying Value $335,273,000 -70%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $602,217,000 -47%
Common Stock, Par or Stated Value Per Share 0.001 0%
Common Stock, Shares Authorized 100,000,000 0%
Common Stock, Shares, Issued 71,860,702 -28%
Deferred Income Tax Assets, Net $37,373,000 -2.2%
Deferred Income Tax Liabilities, Net $410,049,000 -9.7%
Deferred Tax Assets, Gross $423,593,000 +8.5%
Deferred Tax Assets, Net of Valuation Allowance $110,290,000 -20%
Deferred Tax Assets, Operating Loss Carryforwards $259,651,000 +44%
Deferred Tax Assets, Valuation Allowance $313,303,000 +24%
Employee-related Liabilities, Current $496,883,000 -22%
Goodwill $27,508,000
Intangible Assets, Net (Excluding Goodwill) $122,579,000 +1339%
Inventory, Net $96,920,000 -29%
Lessee, Operating Lease, Liability, to be Paid $18,282,000 -67%
Lessee, Operating Lease, Liability, to be Paid, Year Four $2,541,000 -59%
Lessee, Operating Lease, Liability, to be Paid, Year One $3,017,000 -62%
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,499,000 -58%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,551,000 -58%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2,718,000 -75%
Liabilities $2,043,851,000 +3.8%
Liabilities and Equity $12,337,281,000 -9.4%
Liabilities, Current $1,451,898,000 +12%
Operating Lease, Liability $15,564,000 -65%
Operating Lease, Liability, Current $2,366,000 -61%
Operating Lease, Liability, Noncurrent $13,198,000 -66%
Operating Lease, Right-of-Use Asset $16,024,000 -65%
Operating Lease, Weighted Average Discount Rate, Percent 0.044 -10%
Other Assets, Noncurrent $20,488,000 -2%
Other Liabilities, Noncurrent $23,000 -42%
Property, Plant and Equipment, Gross $1,487,214,000 +1%
Property, Plant and Equipment, Net $880,968,000 -7.5%
Retained Earnings (Accumulated Deficit) $6,838,357,000 +0.72%
Stockholders' Equity Attributable to Parent $8,262,258,000 -0.64%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $10,293,430,000 -12%
Unrecognized Tax Benefits $0

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .